GlassScriptPhysician profile
Sarah Ashley Rowe
NPI 1427549765
$12,070.91
in general payments reported to CMS, 2019-2025
59 companies · $3,558 in 2025
The $3,558 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,442 · 2022: $607 · 2023: $1,765 · 2024: $3,699 · 2025: $3,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,566 · Long Term Medical Supply Or Device Loan: $2,131 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,565.77 |
| Long Term Medical Supply Or Device Loan | $2,130.88 |
| Education | $325.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,540.19 | 2021-2025 | |
| Janssen Biotech, INC. | $855.64 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $734.84 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $548.26 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $536.15 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $488.20 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $434.53 | 2021-2025 | Libtayo |
| Abbvie INC. | $401.11 | 2022-2025 | |
| Amgen INC. | $343.46 | 2021-2025 | Evenity, Blincyto, Kyprolis |
| Genzyme Corporation | $303.66 | 2022-2025 | |
| Eisai INC. | $253.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $234.41 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $215.05 | 2021-2025 | Xospata, Xtandi, Vyloy |
| Incyte Corporation | $213.25 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Genentech USA, INC. | $202.49 | 2021-2025 | Venclexta, Tecentriq, Lunsumio |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $198.37 | 2024-2025 | Cabometyx |
| Pfizer INC. | $152.66 | 2024-2025 | |
| Daiichi Sankyo INC. | $139.27 | 2021-2025 | Enhertu |
| Beigene USA, INC. | $138.83 | 2021-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $130.24 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $111.41 | 2021-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $111.26 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Stemline Therapeutics INC. | $109.21 | 2023-2024 | Orserdu |
| Beone Medicines USA, INC. | $93.78 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.65 | 2021-2025 | |
| Gilead Sciences, INC. | $86.65 | 2021-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $83.86 | 2022-2025 | Myrisk |
| Lilly USA, LLC | $83.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.98 | 2024 | Fruzaqla, Ninlaro |
| Sanofi-Aventis U.S. LLC | $77.99 | 2023 | |
| Aveo Pharmaceuticals, INC. | $76.86 | 2021-2025 | |
| Apellis Pharmaceuticals, INC. | $68.29 | 2023-2024 | Empaveli |
| Foundation Medicine, INC. | $68.14 | 2021 | |
| Jazz Pharmaceuticals INC. | $66.91 | 2024-2025 | |
| Puma Biotechnology, INC. | $64.60 | 2024-2025 | |
| Csl Behring | $59.88 | 2021-2024 | Idelvion, Afstyla |
| Seagen INC. | $55.84 | 2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $54.15 | 2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $50.52 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $47.35 | 2021-2023 | Xpovio |
| Pharmacosmos Therapeutics INC. | $45.19 | 2024-2025 | Monoferric, Cosela |
| Adc Therapeutics America, INC. | $38.72 | 2022-2025 | |
| Novocure INC. | $38.15 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $38.00 | 2022 | |
| Servier Pharmaceuticals LLC | $35.09 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $33.04 | 2021 | |
| Kyowa Kirin, INC. | $24.79 | 2025 | |
| Emd Serono, INC. | $23.61 | 2025 | |
| Progenics Pharmaceuticals, INC. | $23.08 | 2022 | |
| Genmab U.S., INC. | $22.81 | 2025 | Epkinly |
| Sobi, INC | $21.90 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.06 | 2024 | Givlaari |
| Morphosys, US INC. | $17.85 | 2023 | Monjuvi |
| Caris Mpi, INC. | $17.75 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $17.44 | 2024 | |
| Dova Pharmaceuticals | $13.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.55 | 2021 | |
| Myovant Sciences INC. | $12.89 | 2021 | |
| Coherus Oncology, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.